Study Purpose: This study looks at how well a new medicine, called RO7790121, works for people with moderate to severe ulcerative colitis (UC). UC is a condition that causes swelling and sores in the colon. The study compares RO7790121 with a placebo, which is a treatment that doesn't contain active medicine.
Eligibility: Participants must have UC and weigh at least 40 kilograms (about 88 pounds). They should have tried other UC treatments that didn't work well for them. They can't join if they have other bowel diseases, certain infections, or are pregnant.
Key Points:
- This study is a Phase III trial, meaning the medicine has already shown promise in earlier tests.
- Participants will be part of the study for both induction and maintenance therapy, which may involve multiple visits.
- There are risks involved, including possible side effects, and participants should discuss these with their doctor before joining.
How understandable was the trial content above?
Hard to understand
Easy to understand